Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Finished Goods (2025)

Outlook Therapeutics (OTLK) has disclosed Finished Goods for 1 consecutive years, with $29626.0 as the latest value for Q3 2025.

  • Quarterly Finished Goods changed N/A to $29626.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $29626.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $29626.0 for FY2025, N/A changed from the prior year.
  • Finished Goods for Q3 2025 was $29626.0 at Outlook Therapeutics, down from $377223.0 in the prior quarter.
  • The five-year high for Finished Goods was $3.3 million in Q1 2025, with the low at $29626.0 in Q3 2025.